177 related articles for article (PubMed ID: 8978598)
1. Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications.
Leto G; Tumminello FM; Pizzolanti G; Montalto G; Soresi M; Gebbia N
Oncology; 1997; 54(1):79-83. PubMed ID: 8978598
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin D, B and L circulating levels as prognostic markers of malignant progression.
Tumminello FM; Leto G; Pizzolanti G; Candiloro V; Crescimanno M; Crosta L; Flandina C; Montalto G; Soresi M; Carroccio A; Bascone F; Ruggeri I; Ippolito S; Gebbia N
Anticancer Res; 1996; 16(4B):2315-9. PubMed ID: 8694562
[TBL] [Abstract][Full Text] [Related]
3. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients.
Kos J; Stabuc B; Schweiger A; Krasovec M; Cimerman N; Kopitar-Jerala N; Vrhovec I
Clin Cancer Res; 1997 Oct; 3(10):1815-22. PubMed ID: 9815568
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity.
Keyszer G; Lambiri I; Keysser M; Keysser C; Nagel R; Burmester GR; Jung K
Z Rheumatol; 1998 Dec; 57(6):392-8. PubMed ID: 10025098
[TBL] [Abstract][Full Text] [Related]
5. Circadian characteristics of cathepsins B, H, L, and stefins A and B, potential markers for disease, in normal sera.
Cimerman N; Brguljan PM; Krasovec M; Suskovic S; Kos J
Clin Chim Acta; 1999 Apr; 282(1-2):211-8. PubMed ID: 10340450
[No Abstract] [Full Text] [Related]
6. Serum concentration and circadian profiles of cathepsins B, H and L, and their inhibitors, stefins A and B, in asthma.
Cimerman N; Mesko Brguljan P; Krasovec M; Suskovic S; Kos J
Clin Chim Acta; 2001 Aug; 310(2):113-22. PubMed ID: 11498076
[TBL] [Abstract][Full Text] [Related]
7. [Enzymatic activity of cathepsin B, cathepsin B and L, plasmin, trypsin and collagenase in hepatocellular carcinoma].
Niewczas M; Paczek L; Krawczyk M; Pawlak J; Bartłomiejczyk I; Górnicka B
Pol Arch Med Wewn; 2002 Jul; 108(1):653-62. PubMed ID: 12412410
[TBL] [Abstract][Full Text] [Related]
8. Tissue Levels of Stefin A and Stefin B in Hepatocellular Carcinoma.
Lin YY; Chen ZW; Lin ZP; Lin LB; Yang XM; Xu LY; Xie Q
Anat Rec (Hoboken); 2016 Apr; 299(4):428-38. PubMed ID: 26753874
[TBL] [Abstract][Full Text] [Related]
9. Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis.
Leto G; Tumminello FM; Pizzolanti G; Montalto G; Soresi M; Carroccio A; Ippolito S; Gebbia N
Pancreas; 1997 Jan; 14(1):22-7. PubMed ID: 8981503
[TBL] [Abstract][Full Text] [Related]
10. Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors.
Lah TT; Nanni I; Trinkaus M; Metellus P; Dussert C; De Ridder L; Rajcević U; Blejec A; Martin PM
J Neurosurg; 2010 May; 112(5):940-50. PubMed ID: 19747051
[TBL] [Abstract][Full Text] [Related]
11. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients.
Levicar N; Kos J; Blejec A; Golouh R; Vrhovec I; Frkovic-Grazio S; Lah TT
Cancer Detect Prev; 2002; 26(1):42-9. PubMed ID: 12088202
[TBL] [Abstract][Full Text] [Related]
12. Cysteine proteases and cysteine protease inhibitors in non-small cell lung cancer.
Krepela E; Procházka J; Kárová B; Cermák J; Roubková H
Neoplasma; 1998; 45(5):318-31. PubMed ID: 9921922
[TBL] [Abstract][Full Text] [Related]
13. Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas.
Trinkaus M; Vranic A; Dolenc VV; Lah TT
Int J Biol Markers; 2005; 20(1):50-9. PubMed ID: 15832773
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin D serum mass concentrations in patients with hepatocellular carcinoma and/or liver cirrhosis.
Leto G; Tumminello FM; Pizzolanti G; Montalto G; Soresi M; Ruggeri I; Gebbia N
Eur J Clin Chem Clin Biochem; 1996 Jul; 34(7):555-60. PubMed ID: 8864404
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin expression in oral squamous cell carcinoma: relationship with clinicopathologic factors.
Kawasaki G; Kato Y; Mizuno A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Apr; 93(4):446-54. PubMed ID: 12029284
[TBL] [Abstract][Full Text] [Related]
16. [Serum stefin A in patients with type 2 diabetes].
Piwowar A; Fus I; Kanapik-Kordecka M; Warwas M
Pol Arch Med Wewn; 2004 Mar; 111(3):319-25. PubMed ID: 15230213
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the activity of lysosomal cysteine proteinases by pH-induced inactivation and/or endogenous protein inhibitors, cystatins.
Turk B; Bieth JG; Björk I; Dolenc I; Turk D; Cimerman N; Kos J; Colic A; Stoka V; Turk V
Biol Chem Hoppe Seyler; 1995 Apr; 376(4):225-30. PubMed ID: 7626231
[TBL] [Abstract][Full Text] [Related]
18. The amino acid sequences, structure comparisons and inhibition kinetics of sheep cathepsin L and sheep stefin B.
Ritonja A; Coetzer TH; Pike RN; Dennison C
Comp Biochem Physiol B Biochem Mol Biol; 1996 Jun; 114(2):193-8. PubMed ID: 8759291
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical staining of cathepsins B, L and stefin A in human hypophysis and pituitary adenomas.
Strojnik T; Lah TT; Zidanik B
Anticancer Res; 2005; 25(1B):587-94. PubMed ID: 15816632
[TBL] [Abstract][Full Text] [Related]
20. Cathepsins B and L are markers for clinically invasive types of meningiomas.
Strojnik T; Zidanik B; Kos J; Lah TT
Neurosurgery; 2001 Mar; 48(3):598-605. PubMed ID: 11270551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
